Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib, randomised, double-blind, placebo-controlled, multiple-dose escalation study evaluating the safety, tolerability and pharmacokinetics of NSI-189 in patients with major depressive disorder.

Next Previous
Trial Profile

A phase Ib, randomised, double-blind, placebo-controlled, multiple-dose escalation study evaluating the safety, tolerability and pharmacokinetics of NSI-189 in patients with major depressive disorder.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NSI 189 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Neuralstem; Seneca Biopharma

Most Recent Events

  • 12 May 2016 Results published in a Neuralstem media release.
  • 08 Dec 2015 Results of this trial were published in Molecular Psychiatry, according to a Neuralstem media release.
  • 08 Dec 2015 Results published in a Neuralstem media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top